dr. neelapu discusses efficacy of axi-cel in large b-cell lymphoma
Published 5 years ago • 92 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
2:24
dr. neelapu on axi-cel in the zuma-1 trial for refractory aggressive non-hodgkin lymphoma
-
1:43
dr. neelapu on third-line car t-cell therapy in large b-cell lymphoma
-
2:02
dr. neelapu on updated zuma-1 findings in non-hodgkin lymphoma
-
6:37
zuma-7: axi-cel in r/r large b-cell lymphoma
-
1:25
dr. neelapu on allo-501 plus allo-647 in relapsed/refractory b-cell lymphomas
-
2:06
zuma-12: axi-cel as first-line therapy in high-risk large b-cell lymphoma
-
5:14
axi-cel and future of car t-cell therapy in lymphoma
-
1:37
sattva neelapu, md, considers the use of axicabtagene ciloleucel with elderly lymphoma patients
-
2:59
axi-cel in older patients: data from zuma-1 and clinical use
-
4:27
cytopenias after axi-cel in r/r large b-cell lymphoma: clinical implications
-
2:32
zuma-1 update: durable survival in r/r dlbcl patients treated with axi-cel
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
3:08
car t cell axi-cel drives b-cell lymphomas into remission
-
3:18
zuma-5: axi-cel for r/r inhl
-
0:43
safety findings for axi-cel in patients with dlbcl
-
3:55
zuma-12: axicabtagene ciloleucel for high-risk large b cell lymphoma
-
0:46
key takeaway from 2-year follow-up data of zuma-1 trial in large b-cell lymphoma
-
0:54
insights into the zuma-23 trial: axi-cel in frontline high-risk lbcl
-
2:33
large b-cell lymphoma: relapsing post-axi-cel